drugset / Trial / NCT01188759

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

NCT01188759

Phase 3 Withdrawn Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

Timeline

Start
2012-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Anidulafungin Other / unclassified 1.5 mg/kg Intravenous
Comparator Voriconazole Small molecule 4 mg/kg Intravenous
Comparator Voriconazole Small molecule 8 mg/kg Intravenous
Comparator Voriconazole Small molecule 9 mg/kg Intravenous
Comparator Voriconazole Small molecule 200 mg Intravenous